OTCMKTS:PBLA Panbela Therapeutics (PBLA) Stock Price, News & Analysis $0.0010 -0.01 (-90.99%) As of 09/22/2026 09:33 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Panbela Therapeutics Stock (OTCMKTS:PBLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Panbela Therapeutics alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range$0.0001▼$0.011152-Week Range$0.00▼$0.15Volume4,673 shsAverage Volume999 shsMarket Capitalization$4.85 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on treatments that target polyamine metabolism, a biological process associated with tumor growth and progression. Panbela’s primary investigational product has been ivospemin, also known as SBP-101, an agent studied in combination with chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. The company has also been associated with Flynpovi, a combination of eflornithine and sulindac being developed to reduce the risk of recurrent colorectal adenomas in people with familial adenomatous polyposis. The company was formerly known as Sun BioPharma and adopted the Panbela Therapeutics name as it expanded its oncology development strategy. Its programs have primarily been evaluated through clinical studies in the United States and other regions. Panbela has been led by executives with experience in biotechnology, drug development and oncology, including Jennifer K. Simpson, who served as president and chief executive officer.AI Generated. May Contain Errors. Read More Receive PBLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBLA Stock News HeadlinesPanbela Therapeutics Inc.June 10, 2026 | barrons.comPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.dePanbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 14, 2024 | globenewswire.comPanbela Therapeutics (OTC:PBLA) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comSee More Headlines PBLA Stock Analysis - Frequently Asked Questions How have PBLA shares performed this year? Panbela Therapeutics' stock was trading at $0.0002 on January 1st, 2026. Since then, PBLA shares have increased by 400.0% and is now trading at $0.0010. How were Panbela Therapeutics' earnings last quarter? Panbela Therapeutics, Inc. (OTCMKTS:PBLA) announced its earnings results on Thursday, August, 10th. The company reported ($159.00) EPS for the quarter, missing the consensus estimate of ($94.20) by $64.80. Read the conference call transcript. When did Panbela Therapeutics' stock split? Panbela Therapeutics's stock reverse split on Thursday, January 18th 2024.The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Panbela Therapeutics? Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/10/2023Today9/23/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:PBLA CIK1029125 Webwww.panbela.com Phone(952) 479-1196FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,850,000Free Float4,855,000Market Cap$4.85 thousand OptionableNot Optionable Beta42.77 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:PBLA) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredMy next big call (under $1)While the Senate was failing to pass the CLARITY Act, the SEC already had its own crypto framework on the tabl...Crypto 101 Media | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
